Glycogen                  storage                    disease (gsd)
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
6,529
On Slideshare
5,536
From Embeds
993
Number of Embeds
5

Actions

Shares
Downloads
295
Comments
0
Likes
4

Embeds 993

http://mdmedicine.wordpress.com 973
https://mdmedicine.wordpress.com 11
http://www.slideshare.net 7
http://translate.googleusercontent.com 1
https://www.linkedin.com 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Glycogen storage disease (gsd)
    Saddam Ansari
    Tbilisi State Medical University
    4th May 2011
  • 2. Introduction
    Glycogen is a branched-chain polymer of glucose and serves as a dynamic but limited reservoir of glucose, mainly in skeletal muscle and liver.
    There are a number of different enzymes involved in glycogen synthesis, utilization and breakdown within the body.
  • 3. Continued…
    Glycogen storage disorders (GSD) are a group of inherited inborn errors of metabolism due to deficiency or dysfunction of these enzymes.
    confined to just liver and muscle
    But some cause more generalised pathology and affect tissues such as the kidney, heart and bowel.
    The classification of glycogen storage disorders is based on the enzyme deficiency and the affected tissue.
  • 4.
  • 5. Epidiomology
    The overall GSD incidence is estimated at 1 case per 20,000-43,000 live births.
    Type I is the most common (25% of all GSD).
  • 6. Inheritance patterns
    Autosomal recessive (I, II, III, IV, V, VII, some IX).
    Both parents are carriers.
    Chance of sibling being affected is 1 in 4.
    X-linked (some IX, VI)
  • 7. Types
    There are eleven (11) distinct diseases that are commonly considered to be glycogen storage diseases
    Although glycogen synthase deficiency does not result in storage of extra glycogen in the liver, it is often classified with the GSDs as type 0.
  • 8. Type I, Von Gierke's disease
    Affected enzyme: glucose-6-phosphatase
    Affected tissue: Liver and kidney
    Clinical features:
    Large quantities of glycogen are formed and stored in hepatocytes, renal and intestinal mucosa cells. The liver and kidneys become enlarged.
  • 9. Abnormalities of lipids may lead to xanthoma formation.
    Uric acid is often elevated and may cause clinical gout. Galactose, fructose, and glycerol are metabolised to lactate. The elevated blood lactate levels cause metabolic acidosis.
  • 10. Treatment
    Blood loss may require oral iron.
    Raised uric acid levels may require allopurinol.
    Treatment of hyperuricaemia and pyelonephritis protect renal function.
    Diazoxide to maintain blood glucose has been disappointing.
    Liver transplantation for primary disease or for hepatocellular carcinoma seems effective.
  • 11. Type II, Pompe's disease
    Cause:
    The deficiency of the lysosomal enzyme alpha-1,4-glucosidase (acid maltase) leads to the accumulation of glycogen in many tissues.
    Clinical feature:
    The clinical spectrum is continuous and broad, with presentation in infants, children and adults.
    In the infantile form, accumulation of glycogen in cardiac muscle leads to cardiac failure.
  • 12. Accumulation may also occur in the liver, which results in hepatomegaly and elevation of hepatic enzymes.
    Glycogen accumulation in muscle and peripheral nerves causes hypotonia and weakness.
    Glycogen deposition in blood vessels may result in intracranial aneurysms.
  • 13. Treatment:
    Enzyme replacement therapy (Alglucosidasealfa)
    Diet therapy may provide temporary improvement but does not alter the disease course: a high-protein, low-carbohydrate diet may be beneficial.
    Physiotherapy and occupational therapy may be required.
  • 14. Genetic counselling and prenatal diagnosis: chorionic villus sampling and amniocentesis can be used to determine enzyme activity in a fetus.
    Gene therapy remains a potentially effective treatment for the future.
  • 15. Type III, Cori disease
    Affected enzyme: Glycogen debranching enzyme. Deposition of abnormal glycogen structure.
    Affected tissues: Liver and muscle.
    Clinical features:
    About 15% affect liver only. Hypoglycaemia, poor growth, hepatomegaly, moderate progressive myopathy.
    Symptoms can regress with age.
    A few cases of liver cirrhosis and hepatocellular carcinoma have been reported.
  • 16. Continued…
    Treatment: As with type I, also protein supplements for muscle disorder.
  • 17. Type IV, Andersen's disease, Amylopectinosis
    Affected enzyme: Glycogen branching enzyme. Abnormally structured glycogen forms.
    Affected tissues: Many, including liver. Rare variant affects peripheral nerves.
    Clinical features:
    Hepatomegaly, failure to thrive, cirrhosis, splenomegaly, jaundice, hypotonia, waddling gait, lumbar lordosis.
  • 18. Continued…
    Treatment: Liver transplant.
    Prognosis: Mostly death by age 4 due to cirrhosis and portal hypertension.
  • 19. Type V, McArdle's disease
    Cause: Myophosphorylase deficiency
    Affected tissue: Muscle
    Clinical features
    Clinical findings may be absent on physical examination. Muscle strength and reflexes may be normal
    In later adult life, persistent proximal weakness and muscle wasting may be present.
  • 20. The fatal infantile form presents with hypotonia and reduced reflexes.
    Ischaemic forearm test: traditional test but is painful and non-ischaemic exercise tests are now preferred.
  • 21. Treatment
    No specific treatment exists.
    Avoid strenuous (anaerobic or sustained) exercise, including lifting or pushing.
    A carbohydrate rich diet did benefit patients.
  • 22. Type VI, Hers disease
    Affected enzyme: Liver phosphorylase.
    Affected tissues: Liver, rare cardiac form.
    Clinical features:
    Most common variant is X-linked therefore usually affects only males.
    Hepatomegaly, hypoglycaemia, growth retardation, hyperlipidaemia.
  • 23. Continued…
    Treatment: Cardiac transplantation for rare cardiac form. May need frequent feeding to avoid hypoglycaemia.
    Prognosis: Usually normal life span.
  • 24. Type VII, Tarui disease
    Cause: Phosphofructokinase (PFK) deficiency
    Affected tissue: Muscle
    Clinical features:
    Exercise intolerance, muscle cramping, exertionalmyopathy, compensated haemolysis and myoglobinuria.
    Note : Symptoms can be similar to McArdle's Glycogen Storage Diseasebut more severe.
  • 25. Treatment:
    No specific treatment exists.
    There is evidence that a high protein diet may improve muscle function and slow progression of the disease.
    Vigorous exercise should be avoided as it causes myoglobinuria.
  • 26. Type XI, Fanconi-Bickel syndrome
    Affected enzyme: Glucose transporter GLUT2[solute carrier family 2 ,facilitated glucose transporter]
    Clinical features: Similar features to Von Gierke's disease, e.g. hypoglycaemia.
  • 27. Type 0, Lewis disease
    Affected enzyme: Hepatic glycogen synthase.
    Affected tissues: Liver.
    Clinical features
    Seizures can occur.
    Fatigue and muscle cramps after exertion.
    Mild growth retardation in some cases.
  • 28. Investigation
    Blood tests:
    Blood glucose: hypoglycaemia is likely
    Liver function tests: monitoring for hepatic failure
    Anion gap calculation: if glucose low, this may indicate lactic acidaemia
    Urate
  • 29. Creatinine clearance
    Creatine kinase
    Full blood count
  • 30. Urine tests:
    Myoglobinuria after exercise found in 50% of people with McArdle's disease.
  • 31. Imaging
    Abdominal ultrasound scan: hepatomegaly
    Echocardiography: to look for cardiac involvement in certain types of GSD
  • 32. Biopsy
    Of liver.
    Muscle or other tissues gives definitive diagnosis.
  • 33. Pre-natal diagnosis
    Genetic counseling.
    Referral to geneticist for possible prenatal investigation (amniotic fluid analysis) and diagnosis.
  • 34. Differential Diagnosis
    In GSD affecting muscle, exclude the muscular dystrophies (including Duchenne's) and secondary disorders of muscle including polymyositis.
  • 35. Acknowledgement